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ABSTRACT
Objective: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation in joints. Ageratum conyzoides L. (Babandotan) 
leaves are proven to be used in inflammation therapy, yet there is a little data regarding the effects of the leaves on RA. The aim of this study is to 
investigate anti-RA activity of the ethanolic extract of A. conyzoides L. leaves (EEAL) harvested from Bogor, Indonesia, in rats.
Methods: The phytochemical screening analysis and thin-layer chromatography were performed to analyze the constituents of the EEAL. This study 
used white male Sprague Dawley rats which were divided into 6 groups; normal control and negative control groups, both given 0.5% carboxymethyl 
cellulose; the positive control group, given methotrexate suspension (0.05 mg/200 g bw.); the dose variation extract is 40 mg, 80 mg, and 160 mg/200 g 
body weight. All the groups were induced with 0.1 ml Complete Freund’s adjuvant on day 1, except normal control group. Some parameters will be 
measured, such as paw edema, levels of leukocyte and lymphocyte, concentrations of tumor necrosis factor-α (TNF-α), and the number of osteoclasts 
per mm2.
Results: For 21 days the rats have given treated the EEAL in three doses, was showed the decreasing volume of paw edema, levels of blood leukocytes 
and lymphocytes, concentrations of TNF-α and the number of osteoclasts, compared to the rat model of RA.
Conclusion: This study showed that the leaves of A. conyzoides L. harvested from Bogor, Indonesia, have activity as anti-RA in a rat model, in which 
flavonoid plays a role in inhibition of chronic inflammatory processes.
Keywords: Ageratum conyzoides L. leaves, Anti-rheumatoid arthritis, Complete Freund’s adjuvant, Flavonoids.
INTRODUCTION
Ageratum conyzoides L. (Asteraceae) (Babandotan), were harvested 
from Bogor, Indonesia, is widely grown in many tropical and subtropical 
countries in Africa, Asia, and the Americas [1-3]. Locally, this plant is 
used traditionally in Indonesia (including in Bogor) and the world, 
as a medicinal plant, especially for inflammation-related disease, yet 
there is a little data regarding the effects of A. conyzoides L. leaves on 
rheumatoid arthritis (RA). A. conyzoides contain secondary metabolites 
such as flavonoids, tannins, alkaloids, saponins, terpenoids/steroids, 
and polyphenols [3-6]. The presence of these metabolites most found in 
the leaves, flowers, and in some parts of the plant [7].
Inflammation is a condition in which the body defends itself from 
injury or attack, such as microorganisms, or any other causes. 
Inflammation is a complex reaction which involves enzyme activation, 
cytokine production, extravasation of fluid, the influx of inflammatory 
cell, tissue breakdown, and repair process of the body. RA is a chronic 
inflammatory disease, primarily affects the joints and leads to the 
proliferation of the synovium, cartilage degradation, and bone erosion. 
The previous study has shown the pro-inflammatory cytokine, such 
tumor necrosis factor-α (TNF-α), and interleukin-1 (IL-1) play an 
important role in the RA process [8-12]. Approximately, 1-2% of the 
world population suffered from RA and cause impaired mobility, 
decreased labor productivity and increased health-care costs. In 
general, the treatment of RA use nonsteroidal anti-inflammatory 
drugs and a group of corticosteroids, yet both of these drugs only 
relieve the symptoms and do not cure the disease. Meanwhile, 
the drugs in the group of disease-modifying antirheumatic drugs, 
i.e., methotrexate which is currently known as the gold standard for 
the treatment of RA, as empirically proven to inhibit the progression 
of RA disease, yet still not cure the disease. In addition, the use of 
these drugs in the long-term can cause various side effects, such as 
gastrointestinal disorders (nausea, vomiting, abdominal discomfort, 
rash, and bleeding) [11,13,14].
Therefore, it is an important to get an alternative therapy which has a 
potential activity for the treatment of RA. This study offers a potential 
activity of A. conyzoides that are widely available in Indonesia and 
also scattered in several places in the world that can be used as an 
alternative/complementary therapies [3-5]. The objective of this 
study is to investigate the anti-RA activity of the ethanolic extract of 
A. conyzoides (Babandotan) leaves (EEAL) harvested from Bogor, 
Indonesia in rats.
METHODS
Plant material and extract preparation
A. conyzoides (Babandotan) leaves as the main material, obtained 
from the Research Institute for Spices and Medicinal Plants 
(BALITTRO), Bogor and determined by the Research Center for Biology, 
Indonesian Institute of Sciences (LIPI) (Certificate of Determination 
No. 206/IPH.1.01/If.07/I/2016). This plant was harvested from 
plants grown in Bogor, Indonesia (Bogor climatic: Temperature 
21.8°C-30.4°C/average 26°C, humidity 70%, rainfall is quite high 
average 3,500-4,000 mm/year, and altitude 190-133 m above sea) [15]. 
Leaves are washed by running water, drained, dried, and ground into 
dry powder. The extraction method is use cold maceration using 70% 
ethanol (1:5) (3×24 hrs) to obtain a thick extract [16]. The results were 
obtained, weighed, and stored in dark glass bottles (yield: 16.2% w/w).
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Drugs and chemicals
The chemicals used in the study is 70% ethanol solution (Brataco 
Chemistry, Indonesia), distilled water (Brataco Chemistry, Indonesia), 
neutral saline 0.9% (Otsuka, Indonesia), methotrexate (Ebewe Pharma, 
Austria), Complete Freund’s adjuvant (CFA) containing Mycobacterium 
tuberculosis (Sigma-Aldrich, USA), and ketamine (Hameln, Germany).
Animal
The animal test uses Sprague Dawley rats which obtained from the 
IPB husbandry, Bogor. The weight of rats is between 175 and 250 g. 
The rats were randomly divided into 6 groups with each group are 
consist of five rats. The group is conditioned in a cage under standard 
laboratory conditions, with a light cycle 12 h light on/12 h light off 
(dark), temperature 22°C-25°C, humidity 40-60%, the rats get access 
to food water freely, and do tag as identity. Acclimation is performed for 
7 days and during the time conducted routine observations concerning 
the general condition and body weight. This research has certified by 
ethical certification of Faculty of Medicine, University of Indonesia (UI 
FK No. 75/UN2.F1/Ethics/2016) for the use of animals in experiments.
Characterization of extract and chromatographic analysis
The organoleptic examination results of the extract are has a greenish 
black color, specifically has a Babandotan odor and slightly bitter taste. 
The results of non-specific parametric of the EEAL are moisture content 
was 9%, total ash content was 0.97%, acid insoluble ash content was 
0.04%, and the levels of the solvent residue was negative (test using GC). 
Phytochemical screening observation found that the EEAL containing 
some chemicals metabolites such as flavonoids (produce a red color 
due to the addition of Zn and Mg, and formed yellow bluish fluorescence 
using ultraviolet light 366 nm), tannins (white deposits by giving 
gelatin and gelatin+NaCl), alkaloids (solid white precipitate formed 
by providing reagents Mayer’s, blackish brown color by giving reagent 
bouchardat), terpenoids steroids (bluish green color), and saponins 
(froth-formed with a diameter of 1.5 cm). Total flavonoid was 2.31% by 
spectrophotometry. Thin-layer chromatography used silica plates F254 
as the stationary phase for chromatographic characterization of the 
extract. A total of 10 mg extract was weight and dissolved with 10 ml of 
ethanol. And the mobile phase used toluene:Ethyl acetate:Formic acid 
at a ratio of 58:33:9, as well as equal with quercetin.
Induction of arthritis with CFA
A total of 30 rats (Sprague Dawley) were induced by CFA (1 mg/ml; 
0.1 ml) and were injected in the left hind paw subcutaneously on the 
1st day and given a 4-week waiting period to form a rat model of RA [17], 
except for the normal control group. The rats were divided into 6 Groups 
(I-VI), each group was consist of five rats, i.e., Group I (normal control) 
and Group II (negative control) applied carboxymethyl cellulose 0.5%, 
Group III (positive control) applied methotrexate 0.05 mg/200 g bw./d 
and Groups IV, V, and VI applied the EEAL in three different doses 
(40, 80, and 160 mg/200 g bw./d) during 21-day period. At day 29, 
rats were measured for paw edema volume, and level of leukocytes 
and lymphocytes. At day 50, rats were also measured for paw edema 
volume, the level of leukocytes and lymphocytes, and then measured for 
TNF-α concentration, and subsequently, rats were killed to evaluate the 
number of osteoclast at calcaneus bone.
Examination of anti-inflammation activity
Using mercury plethysmometer measurement, edema volume of left 
hind paw rats was observed and recorded before CFA injection on 
day 1, and further observation on day 29 and 50. The percentage of 
inhibition of paw edema volume was measured on day 50, and the data 
were analyzed by comparing the outcomes between the 6 groups. The 
percentage inhibition of paw edema volume was calculated using the 
following formula:
[(Vc−Vt)/Vc]×100
Where Vc is the average value of the paw edema volume by control 
group, and Vt is the average value of the paw edema volume by the test 
group [16].
Measurement of blood leukocytes and lymphocytes levels
Blood samples were collected from retro-orbital plexus on day 29 and 
50, mixed with ethylenediamin etetraacetic acid (EDTA) to prevent 
coagulation of blood and then measured with a hematology analyzer. 
Results of blood leukocyte and lymphocyte levels were recorded and 
analyzed.
Measurement of TNF-α concentration
Blood samples were collected from retro-orbital plexus on day 50, 
(without mixing with EDTA) and then measured with a hematology 
analyzer. The blood sample was stored at room temperature for 30 min 
and then centrifuged at 3.000 rpm for 10 min. The resulting serum 
was collected and stored at −20°C. The content of the cytokine TNF-α 
concentration was measured using enzyme-linked immunosorbent 
assay (ELISA) kit by applying optical density absorbance wavelengths 
of 450 nm and in accordance with manufacturer’s procedures. ELISA 
reader shows the results and further data were analyzed.
Measurement of number of osteoclasts
In the previous study, we found that RA made bone resorption in 
the heel joint especially calcaneus bone [18]. Hence, we evaluated 
calcaneus bone by calculating osteoclast number on that bone. On the 
day 50, the rats were set up to performed surgery to isolate the joints 
(region tibiotarsal) longitudinally midline [19]. The histopathology 
of calcaneus bone was made by fixation, decalcification, dehydration, 
purification, and infiltration/embedding in paraffin blocks, and 
cutting (3-5 µm), finally stained by hematoxylin-eosin staining (H&E). 
A number of osteoclasts at calcaneus bone were observed using a 
microscope (×400). Osteoclasts are calculated based on the total 
number of osteoclasts per measuring area (mm2) (Total Noc/Tar) and 
data were analyzed [20].
RESULTS
Phytochemical screening and chromatographic characterization
Preliminary phytochemical screening revealed the presence of 
chemical metabolites such as flavonoids, tannins, alkaloids, terpenoids 
steroids, and saponins. Thin-layer chromatography appearance results 
showed flavonoids with Rf value was 0.53, which almost equivalent to 
the standard solution, quercetin with Rf value was 0.52. It indicated 
that in the EEAL, there were secondary metabolites such as flavonoids 
equivalent to quercetin (Fig. 1). The result showed that the EEAL 
characterization has met to the specification of Indonesian Herbal 
Pharmacopoeia [21-23].
Effect on paw edema volume
Anti-RA activity of the EEAL on rat paw edema induced by CFA (n=5) is 
shown in Fig. 2a. Paw edema volume was measured by plethysmometer 
on day 29 and 50. On day 50 shown that the three EEAL doses can 
be reduced paw edema volume significantly (p<0.05) within 21 days 
treatment (in Dose I: 1.24; Dose II: 1.22; Dose III: 1.1) compared to 
edema volume for the negative control group (1.88). Edema inhibitory 
activity of the EEAL was found 34.04% in Dose I, 35.10% in Dose II, 
and 41.49% in Dose III on day 50th. The edema inhibitory activity was 
highest in doses of 160 mg/200 g bw./d of the EEAL but lower than 
positive control, methotrexate (53.19%) (Fig. 2b). Application of the 
EEAL showed inhibitory activity edema in rats induced by CFA, and also 
showed the anti-inflammatory effect on chronic inflammation.
Effect on level of blood leukocytes and lymphocytes
Anti-RA activity of the EEAL is showed by the levels of blood leukocytes 
and lymphocytes are shown in Fig. 3. It is shown by observation on 
day 29 and 50 that the reducing of blood leukocytes levels caused by 
suppression of the EEAL activity compared to the negative control 
group; It obtained the results as follows: Dosage I: 13.6 and 13.7; 
Dosage II: 14.4 and 13.7; Dosage III: 14.2 and 11.5. Moreover, it 
was showed on day 50, the reducing of blood leukocytes level was 
significant seen (p<0.05) in the dosage of 160 mg/200 g bw./d of the 
EEAL compared to negative control groups (14.0 and 16.2) and similar 
to the positive control group, (methotrexate [15.2 and 11.0]). The 
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reducing of blood lymphocytes level caused by suppression activity 
of the EEAL compared to the negative control group that observed on 
day 29 and 50; It showed, i.e.: In Dosage I: 9.0 and 7.8; Dosage II: 9.5 
and 6.5; Dosage III: 11.1 and 7.4. There is a significant decrease in the 
levels of lymphocytes (p<0.05) on the three EEAL dosage variation 
treatment, compared with negative controls group (10.1 and 11.0). 
This observation shows similar results when compared to the positive 
control group (methotrexate [9.6 and 7.3]).
Effect on TNF-α concentration
Effect of anti-RA activity of the EEAL against TNF-α concentration in 
the rat is shown in Fig. 4. TNF-α concentration suppression activity 
of the EEAL was analyzed by ELISA kit and was found 274.3 pg/ml in 
Dosage I, 236 pg/ml in Dosage II, and 244.3 pg/ml in Dosage III on day 
50. As shown in the results, concentration of TNF-α group AR rat model 
increased when compared to normal control group. The concentration 
of TNF-α was reduced by the administration of three dose levels of the 
EEAL compared to the negative control group (316 pg/ml) but higher 
than the positive control group, (methotrexate [232.6 pg/ml]). The 
EEAL showed inhibitory activity concentrations of TNF-α and it shows 
the anti-inflammatory effect on chronic inflammation.
Effect on number of osteoclasts
Observation number of osteoclasts in calcaneus bone by histopathology 
examination in rats induced CFA showed an increased amount 
compared with the normal control group. This result was a similar 
result in a previous study [18]. Anti-RA activity of three doses levels of 
Fig. 1: Thin layer chromatography spotting of the ethanolic 
extract of Ageratum conyzoides L. leaves (EEAL). (a) Light 254 nm, 
(b) light 366 nm; P=Comparative quercetin, S=A. conyzoides 
leaves extract, Asterisk (*) Rf=comparison value quercetin 0.52; 
Rf no. 4 (value of 0.53)
ba
Fig. 2: (a) Anti-rheumatoid arthritis activity of the EEAL on 
CFA-induced paws edema in rats on day 29th and 50th. Data are 
expressed as mean±standard deviation (n=5). Statistical analysis 
was performed by one-way ANOVA and Kruskall–Wallis followed 
by multiple comparison tests *p<0.05, (b) inhibitory activity of 
the HEAL on CFA-induced paw edema in rats on day 50th
b
a
Fig. 3: Anti-rheumatoid arthritis activity of the EEAL on level 
of leukocytes and lymphocytes in rats in all treatment groups 
on day 29th and 50th. (a) Level of leukocytes, (b) level of 
lymphocytes; data are expressed as mean±standard deviation 
(n=5). Statistical analysis was performed by Kruskall–




Fig. 4: Anti-rheumatoid arthritis activity of the EEAL on 
tumor necrosis factor-α titer in rats is shown in all treatment 
groups on day 50th. (a) OD450 tumor necrosis factor-α (TNF-α) 
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the EEAL proven to reduce the number of osteoclasts compared to the 
negative control group. After 21 days of treatment, the results showed 
the reducing number of osteoclasts was significant seen (p<0.05) in 
the dosage of 160 mg/200 g bw./d of the EEAL compared to negative 
control groups. The total number of osteoclasts per mm2 in each group 
at day 50 was as shown in Fig. 5.
DISCUSSION
RA is a chronic inflammatory disease associated with the immune 
system. Inflammation begins with an increased of capillary permeability 
that allows the inflammatory cells (neutrophils and leukocytes) in the 
blood vessels to reach into inflammation areas which cause fluid influx. 
The body will attempt to stop the inflammatory process, but when the 
attempt went unsuccessful, the process will develop into a chronic 
inflammation. The chronic inflammation, usually associated with the 
immune system and which inflammatory cells such as mononuclear 
cells (lymphocytes and monocytes) will play a dominant role rather 
than PMN cells. In this study, a rat model induced by CFA containing M. 
tuberculosis. The CFA-induced arthritis rat model had extensively used 
as a laboratory model and has been reported successful to create RA 
rats model [19,24,25]. Rats were induced by CFA in the left hind paw 
subcutaneously on day 1 and then wait up to 4 weeks, to formed RA 
rats model [17].
A. conyzoides leaves were purchased in Bogor, Indonesia, where 
local communities traditionally use Babandotan leaves for the 
treatment of inflammatory disease in their daily live, such as fever, 
swelling, soreness, stiffness, wound, and abdominal discomfort. From 
preliminary screening, the result showed that the EEAL was containing 
various secondary metabolites such as flavonoids, tannins, alkaloids, 
terpenoids sterol, and saponins. Thin layer chromatography result 
showed flavonoids was equivalent to quercetin. Flavonoids have 
the core structure of the C6-C3-C6, two aromatic rings connected by 
3 C atoms, typically with O atoms bond which form a heterocyclic 
oxygen bond [26]. The mechanism of anti-inflammatory flavonoid 
can be explained in some way such as inhibiting the activity of the 
enzyme cyclooxygenase and lipooxygenase, inhibition of leukocyte 
accumulation, inhibition of neutrophil degranulation, histamine 
release, and inhibition anti-inflammatory activity (such as inhibiting 
production and activities pro-inflammatory cytokines). Quercetin, a 
member of flavonoids, has been extensively reviewed on its effects on 
inflammatory processes [27].
This study showed that the EEAL can inhibit the process of RA 
significantly in CFA-induced rat paw edema (especially in Dose III; 
160 mg/200 g bw.) compared to the negative control group. The 
previous study by Moura et al., 2005, [4] showed that the hydroalcoholic 
extract of A. conyzoides leaves (250 mg/kg bw.; p.o.) had a 38% 
(p<0.05) reduction in cotton pellet granuloma and the development of 
chronically induced paw edema was also reduced significantly (p<0.05) 
by the plant extract. Paw edema due to acute inflammation allowed 
the influx of inflammation cells and fluid into the inflamed area. The 
decrease of TNF-α concentration affects a decreased volume of paw 
edema, through inhibition of cyclooxygenase. The increased of paw 
edema inhibition of the EEAL showed that flavonoids had the anti-
inflammation effect through the mechanism of action in inhibiting the 
activity of inflammatory cells and pro-inflammation cytokines in CFA-
induced rats. The EEAL dose used in the study was according to the 
previous studies [4] and was explained that hydroalcoholic extract of 
A. conyzoides has low toxicity/LD50 (>5.000 mg/kg, p.o) which make it 
relatively safe to use [5,28].
On the level of blood leukocytes test result, it is shown that giving the 
EEAL can reduce the level of blood leukocytes compared to negative 
control, as well as the blood lymphocytes because the inflammatory 
process that occurred was inhibited by flavonoids. Recent studies by 
Diallo et al., 2010, [28] showed flavonoid from the extract of A. conyzoides 
lowered white blood cells (WBC) in treated rats. CFA-injected in rats 
caused chronic inflammation, which makes the level of blood leukocyte 
and lymphocyte increased on day 29. The EEAL which contains 
flavonoids can inhibit the release of pro-inflammation cytokines such 
as TNF-α which can increase the infiltration of inflammatory cells into 
the inflamed area, that showed on day 50 [4,29,30].
The treatment by giving the EEAL, which contained quercetin, can 
decrease the concentration levels of TNF-α compared to negative 
control. Previous studies by Nair et al. 2005 [27] explained that 
quercetin significantly inhibited TNF-α production and down-regulated 
gene expression in a dose-dependent manner. Anti-inflammation 
effect of quercetin by PBMCs (peripheral blood of mononuclear cells) 
which are mediated by inhibition of pro-inflammatory cytokine 
TNF-α via inhibiting activation of NF-kB. TNF-α is a pro-inflammatory 
cytokines which have an important role in the inflammatory process, 
such as increasing adhesion and infiltration of inflammatory cells into 
the inflamed area, increasing spending of other pro-inflammatory 
cytokines (such as IL-1, IL-2, and IFN-γ), increasing the occurrence 
of angiogenesis, thus simplifying the pannus and cause damage to 
the articular cartilage and bone so that further aggravate the state of 
RA [27,31].
In parameter on osteoclast counting, giving the EEAL can reduce the 
number of osteoclasts in calcaneus bone rats compared to negative 
control. The osteoclast is bone cells that play an important role in the 
absorption and bone regeneration [32]. Recent studies by Almarestani 
et al. 2011 [17] explained that induction CFA (1 mg/ml; 0,15 ml) 
subcutaneously in rats by day 15 showed joint and periarticular swelling 
with widened joint space at the MTP joints as an early sign of arthritis, 
and by day 30 showed soft tissue swelling, erosions, joint deformity, 
periosteal new bone formation, and trabecular bone thickness were 
further reduced. The increase of TNF-α concentration can elevate the 
amount of RANKL-RANK bond which also increases the production 
and activity of osteoclast, causing bone erosion that may worsen the 
RA disease [33-35]. Studies by Stolina et al. (2005) [36] showed that 
RANKL significantly increased during inflammatory arthritis in rats 
that associated with bone erosions and RANKL inhibition through OPG 
prevented local and systemic bone loss in arthritis models. Secondary 
metabolites such as flavonoids contained in the EEAL can inhibit the 
production and activity of TNF-α, so there was no excessive increase in 
the number and activity of osteoclasts.
CONCLUSION
The EEAL harvested from Bogor, Indonesia has an activity of anti-RA 
in rats model, and flavonoids play an important role in inhibiting the 
progressivity of RA disease. These results also corroborate experimental 
evidence of traditional usage of A. conyzoides L. (Babandotan) leaves by 
local communities in Bogor, Indonesia in handling various inflammatory 
diseases, particularly RA.
Fig. 5: Total number of osteoclast per mm2 in all treatment 
groups on day 50th. N=Normal controls, NC=Negative controls, 
PC=Positive controls, DO I=EEAL 40 mg/200 g bw./d, DO II=EEAL 
80 mg/200 g bw./d, and DO III=EEAL 160 mg/200 g bw./d. Data 
are expressed as mean±standard deviation (n=5). Statistical 
analysis was performed by Kruskall–Wallis followed by Mann–
Whitney’s multiple comparison tests *p<0.05
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